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Abstract
Background: Impaired mitochondrial function is fundamental feature of heart failure (HF) and myocardial ischemia. In
addition to the effects of heightened oxidative stress, altered nitric oxide (NO) metabolism, generated by a mitochondrial
NO synthase, has also been proposed to impact upon mitochondrial function. However, the mechanism responsible for
arginine transport into mitochondria and the effect of HF on such a process is unknown. We therefore aimed to characterize
mitochondrial L-arginine transport and to investigate the hypothesis that impaired mitochondrial L-arginine transport plays
a key role in the pathogenesis of heart failure and myocardial injury.
Methods and Results: In mitochondria isolated from failing hearts (sheep rapid pacing model and mouse Mst1 transgenic
model) we demonstrated a marked reduction in L-arginine uptake (p,0.05 and p,0.01 respectively) and expression of the
principal L-arginine transporter, CAT-1 (p,0.001, p,0.01) compared to controls. This was accompanied by significantly
lower NO production and higher 3-nitrotyrosine levels (both p,0.05). The role of mitochondrial L-arginine transport in
modulating cardiac stress responses was examined in cardiomyocytes with mitochondrial specific overexpression of CAT-1
(mtCAT1) exposed to hypoxia-reoxygenation stress. mtCAT1 cardiomyocytes had significantly improved mitochondrial
membrane potential, respiration and ATP turnover together with significantly decreased reactive oxygen species
production and cell death following mitochondrial stress.
Conclusion: These data provide new insights into the role of L-arginine transport in mitochondrial biology and
cardiovascular disease. Augmentation of mitochondrial L-arginine availability may be a novel therapeutic strategy for
myocardial disorders involving mitochondrial stress such as heart failure and reperfusion injury.
Citation: Williams D, Venardos KM, Byrne M, Joshi M, Horlock D, et al. (2014) Abnormal Mitochondrial L-Arginine Transport Contributes to the Pathogenesis of
Heart Failure and Rexoygenation Injury. PLoS ONE 9(8): e104643. doi:10.1371/journal.pone.0104643
Editor: Junichi Sadoshima, Rutgers New Jersey Medical School, United States of America
Received May 21, 2014; Accepted July 11, 2014; Published August 11, 2014
Copyright:  2014 Williams et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: Funding provided by NHMRC Program Grant 1036352. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: david.kaye@bakeridi.edu.au
. These authors contributed equally to this work.
Introduction
Heightened oxidative stress is a key feature of numerous chronic
diseases including cardiovascular disease and neurodegenerative
diseases. In particular the generation of reactive oxygen species
(ROS) and reactive nitrogen species (RNS) is now considered to be
a central contributor to the development and progression of many
diseases, via a range of effects including the oxidative and
nitrosative damage of proteins, enzymes, lipids, DNA and cellular
membranes [1]. Within the heart, elevated oxidative stress has
been reported to play a key role in the pathogenesis of heart failure
and ischemia reperfusion injury [2–4]. Several sources of cellular
ROS production are recognized in the myocardium including the
mitochondrial electron transport chain, NADPH oxidase, xan-
thine oxidase and cytoplasmic NO synthase (NOS) [1], however
the relative contribution of each source to overall cellular ROS
production has not been clearly defined.
Mitochondrial dysfunction is increasingly understood to be
central to the pathophysiology of heart failure and ischemia-
reperfusion injury [5,6]. Recent data indicate that oxidative
inhibition of complex I or III of the mitochondrial transport can
further increase ROS production most likely due to post-
translational modifications [7]. In this context, it has been shown
that NO may exert a cardioprotective effect by mitigating
oxidative damage of components of the electron transport chain
by site-specific S-nitrosation [7–9].
Whilst the mechanism underpinning the protective effect of NO
within mitochondria is emerging, it remains controversial as to
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whether NO is derived from mitochondrial or non-mitochondrial
sources. In this regard, the presence of a mitochondrial NOS has
been reported by several groups as recently reviewed [10]. In this
context, some investigators have estimated that a mitochondrial
NOS may contribute up to 56% of total cellular production of NO
in the heart [11].
Notwithstanding the specific characterization of a mitochondri-
al NOS, it has been demonstrated that the generation of NO by
mitochondria is influenced by the concentration of L-arginine
[12]. In this context, it is unclear how L-arginine enters
mitochondria and whether this process is altered in cardiovascular
disease. Plasmalemmal arginine transport is predominantly
mediated by the system y+ carrier, which is characterized by
sodium independent transport of the cationic amino acids. At
normal physiological concentrations of L-arginine the cationic
amino acid transporter type 1, CAT-1, is the predominant cellular
transport system [13]. Previously, we have shown that CAT-1
mediated L-arginine transport is reduced in the setting of heart
failure and hypoxia-reperfusion [14–16]. In the current study we
aimed to characterize the presence and activity of CAT-1 in
cardiac mitochondria and to determine whether altered mito-
chondrial L-arginine transport contributes to the pathophysiology
of heart failure and ischemia reperfusion injury.
Materials and Methods
The research projects were approved by the Department of
Primary Industry Animal Ethics Committee, and the Alfred
Medical Research and Education Precinct Animal Ethics Com-
mittee. The investigations conform to the NHMRC Australian
code of practice for the care and use of animals for scientific
purpose, and the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health.
Animal Models of Heart Failure and Isolation of Cardiac
Mitochondria
Two animal models of heart failure were employed in the
present study. Heart failure was induced in adult sheep by rapid
ventricular pacing or tachycardia at 190 beats per minute for four
weeks as previously described [17]. In brief, pacemakers were
implanted under anesthesia using propofol and isoflurane. At the
end of the pacing period, animals were killed by pentobarbitone
overdose (100 mg/kg) and hearts were immediately excised and
washed in ice-cold PBS prior to mitochondrial isolation. In
addition to the sheep model, 16 week old transgenic mice with
dilated cardiomyopathy due to cardiac specific overexpression of
Mst1 [18] (kindly provided by Dr Julie McMullen, Baker IDI) and
littermate controls were also investigated in this study. Mice were
killed by pentobarbitone overdose (150 mg/kg i.p.).
Mitochondrial Isolation and Purity
Following cardiac excision, hearts were immediately immersed
in ice cold isolation buffer (Mannitol 200 mM, Sucrose 50 mM,
KH2PO4 5 mM, EGTA 1 mM, MOPS 5 mM, BSA 0.1%,
pH 7.2). For sheep studies, transmural samples of the left ventricle
were obtained from the mid-anterior wall. Cardiac tissue was
thoroughly minced into ,1 mm pieces and rinsed with isolation
buffer. Tissue pieces were transferred to an ice-cold glass
homogeniser vessel containing isolation buffer and 1 mg/ml
protease (Sigma) and homogenised for 30 seconds using a Teflon
homogeniser pestle [19,20]. The tissue homogenate was subse-
quently transferred to an ice-cold 50 mL homogeniser vessel and
diluted 10-fold and homogenised for a further 30 seconds. The
tissue homogenate was then centrifuged at 8000 g for 10-minutes.
The supernatant was discarded and the pellet was carefully re-
suspended and then centrifuged at 700 g for 10 minutes. The
supernatant containing the mitochondrial fraction was collected
and transferred into fresh isolation buffer without EGTA or BSA
and centrifuged at 8000 g for 10 min and the resulting pellet was
re-suspended in ice cold isolation buffer without EGTA/BSA and
kept on ice until required.
Mitochondrial purity was confirmed by western blotting for a
mitochondrial specific protein, 70 kDa subunit of Complex II,
together with demonstration of exclusion of the plasmalemmal
Na+K+ATPase (in mice) or N-cadherin (in sheep). To determine
whether the mitochondrial preparations were in a coupled state,
mitochondrial respiration (oxygen consumption rates) was mea-
sured using a Seahorse XF24 Extracellular Flux Analyser (Sea-
horse Bioscience, Billerica, USA). Briefly, mitochondria (15 ug)
were loaded into XF24 plates in 50 ul basal MAS (Seahorse
Bioscience) buffer. Plates were subsequently centrifuged at 2500 g
for 20 mins at 4 degrees. Mitochondria were then warmed by the
addition of warmed (37uC) MAS buffer containing succinate
(10 mM) and rotenone (2 uM). Basal respiration was established
after the samples were allowed to equilibrate in the seahorse
XF24, followed by injection of ADP (1 mM) to initiate State 3
respiration, then sequential injection of the ATP synthase inhibitor
oligomycin, the proton ionophore carbonylcyanide p-trifluoro-
methoxyphenlhydrazone (FCCP) and the complex III inhibitor
antimycin A, (all 1 mM) to allow for calculation of respiratory
control ratios (state3/state 4 ratio). Mitochondrial membrane
potential was also assessed to confirm the viability of isolated
cardiac mitochondria using the fluorescent probe 5,59, 6,69,-
tetrachloro-1,1,3,39-tetraethylbenzimidazolylcarbocyanine iodide
(1.5 mM JC-1, Molecular Probes, Eugene, OR, USA) [21] in the
presence and absence of 2 mM FCCP and 2 mM antimycin A
(respiratory chain inhibitor). Green and red fluorescence were
measured at 485 nm/535 nm and 485 nm/590 nm (excitation/
emission) respectively, and results expressed as a ratio of red/green
raw fluorescence units (RFU).
Mitochondrial [3H]-L-Arginine Uptake
Cardiac mitochondrial L-arginine transport was characterised
by treating isolated mitochondria with various mitochondrial
inhibitors as well as inhibitors or competitors of the y+ transport
system, comprising L-lysine (10 mM), NEM (200 uM) and
antimycin (2 uM). Mitochondrial pellets were re-suspended in
uptake buffer (220 mM sucrose, 5 mM MgCl2, 20 mM KCl,
10 mM KH2PO4, 10 mM HEPES/KOH, 10 mM sodium
succinate, pH 7.4) and L-Arginine uptake was measured using
radiolabeled [3H]-L-Arginine (specific activity 58 Ci/mmol,
Perkin Elmer Life Sciences, Boston, MA, USA). Solutions
containing 100 nM [3H]-L-arginine and increasing concentrations
of unlabelled L-arginine (0.75–500 mM) were prepared in uptake
buffer and incubated for 15 minutes at 37uC. Pellets were washed
then resuspended in 0.5% SDS and measurement of radioactivity
was made using liquid scintillation spectrometry. CAT1 mediated
L-Arginine uptake was calculated as the difference between total
uptake and 10 mM L-lysine sensitive uptake. Data is presented as
nmol arginine uptake/mg protein.
CAT-1 protein expression in isolated cardiac
mitochondria
Mitochondrial protein (20–30 mg) was subjected to SDS-PAGE
analysis using 7.5% acrylamide gels. After transfer, membranes
were blocked for 1 hour at room temperature in 5% w/v skim
milk, then incubated with CAT-1 antibody (1:1000 in 5% w/v
BSA, 1X TBS, 0.1% Tween20, polyclonal rabbit anti-CAT-1
Mitochondrial Arginine Transport in HF
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Figure 1. Western blot demonstrating reduced CAT1 expression in failing sheep mitochondria, normalized to expression of the
70 kD subunit of complex II (A). Western blot confirming the absence of contaminating sarcolemmal (N-cadherin) or cytosolic (GAPDH) proteins
in mitochondrial preparation (B). Western blots showing reduced CAT1 in failing mouse mitochondria (C). Sarcolemmal Na+K+ATPase is absent from
the mitochondrial preparation compared to crude homogenate (+ve). Bar graphs showing CAT1 expression in sheep (D) and mice (E) (n = 4 per gp).
doi:10.1371/journal.pone.0104643.g001
Mitochondrial Arginine Transport in HF
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custom made by Rockland Immunochemicals, Gilbertsville, PA,
USA) overnight at 4uC. Signal detection was performed by
chemiluminescence. Quantitative densitometric analysis was
performed (Bio-Rad laboratories) and CAT-1 protein expression
levels were indexed to 70 kDa subunit of mitochondrial complex
II.
Measurement of nitric oxide (NO) generation by isolated
mitochondria and 3-nitrotyrosine as a marker of
peroxynitrite formation
NO production in isolated mitochondria (20 mg) from healthy
and failing hearts was measured in triplicate using 5 mM 4-amino-
5-methylamino-29,79-dichlorofluorescein diacetate (DAF-FM, Mo-
lecular Probes, Eugene, OR, USA) as previously described [16].
Evidence of nitrosative stress was determined by measuring 3-
nitrotyrosine levels in mitochondria isolated from healthy and
failing hearts using a OxiSelect Nitrotyrosine competitive ELISA
kit (Cell Biolabs Inc; San Diego, CA, USA).
Mitochondrial CAT-1 overexpression in cardiomyocytes
Neonatal rat ventricular cardiomyocytes (NVCMs) were used
for all cellular studies. NVMCs from D1-3 neonatal rats were
isolated by enzymatic digestion as previously described [16]. Full
length mouse CAT-1 was cloned into a vector (pPhi-yellowFP-
mito, Evrogen, Moscow, Russia) containing a mitochondrial
targeting sequence (MTS) to generate pCAT1-PhiYFP-MTS.
Figure 2. L-Arginine uptake was assessed in healthy and heart failure cardiac mitochondria from A. sheep (n=5–7 per gp) and B.
mice (n=4 per gp) by measuring [3H]-L-arginine influx (15 mins incubation time) in the presence of varying concentrations of
unlabeled L-arginine in. Data is presented as mean 6 SEM.
doi:10.1371/journal.pone.0104643.g002
Mitochondrial Arginine Transport in HF
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e104643
Figure 3. Mitochondrial [3H]-L-arginine uptake was measured in the presence of L-lysine (10 mM), NEM (200 mM) or antimycin
(2 mM) (n=5–7 per gp). Data is presented as mean 6 SEM. *p,0.05 vs. control.
doi:10.1371/journal.pone.0104643.g003
Figure 4. Representative fluorescent confocal images of cardiomyocytes (NVCMs) transfected with control YFP-MTS AAV6 (top
panels) or CAT1-YFP-MTS AAV6 (lower panels) incubated with Mitotracker Red. Images confirm mitochondrial targeting in CAT1-YFP-MTS
AAV6 transfected cardiomyocytes. Scale bar = 10 mm.
doi:10.1371/journal.pone.0104643.g004
Mitochondrial Arginine Transport in HF
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CAT1-PhiYFP-MTS or PhiYFP-MTS were then cloned into the
Adeno-Associated Virus (AAV) Vector pAAV-CMV-MCS-
SV40pA-deltahPLAP to generate AAV6-CAT1-PhiYFP-MTS or
AAV6-PhiYFP-MTS. Transfected cells were then subjected to
various mitochondrial stresses including hypoxia/reoxygenation (3
hours hypoxia followed by 2 hours normoxia) [16] or exposure to
the mitochondrial respiratory chain inhibitor, antimycin A
(0.5 mM) for 5 hours. ROS production, mitochondrial membrane
potential, mitochondrial respiration and ATP turnover along with
lactate dehydrogenase release were then measured. ROS produc-
tion was measured with 10 mM 29,79-dichlorodihydrofluorescein
diacetate (H2DCF-DA, Molecular Probes) and mitochondrial
membrane potential using the fluorescent probe JC-1 both as
previously described [16]. Mitochondrial localisation of CAT-1
within cardiomyocytes was investigated by confocal microscopy
with 50 nM MitoTracker Red (Molecular Probes Eugene, OR,
USA).
Mitochondrial function was also examined in cells transfected
with CAT1-YFP-MTS or YFP-MTS AAV following hypoxia/
reoxygenation using the Seahorse XF24 Extracellular Flux
Analyser. Briefly, NVCMs were plated into 24well Seahorse V7
plates at 66104 cells/well, as described above. Basal energetics
were then established through the simultaneous measurement of
oxygen consumption rate (OCR) and extracellular acidification
rate (ECAR) in the Seahorse XF24, followed by sequential
injection of oligomycin, FCCP and antimycin A (all 1 mM) to
allow for calculation of basal respiration, OCR attributable to
ATP turnover, uncoupled respiration and maximal and spare
respiratory capacity. Mitochondria were also isolated from
NVCMs as previously described [22]. Studies were performed in
triplicate over at least three independent experiments.
Statistical analysis
Data was analysed with by either Student t-tests or by one-way
analysis of variance (ANOVA) followed by Bonferonni post-hoc
tests for multiple comparisons. All statistical tests were performed
using GraphPad Prism program, version 6 (GraphPad Software,
San Diego, USA), and p,0.05 was considered indicative of
statistical significance. All data are presented as mean 6 SEM.
Results
Mitochondrial CAT-1 expression in healthy and failing
hearts
To investigate the hypothesis that a specific L-arginine
transporter is present within cardiac mitochondria, we conducted
western blotting on mitochondrial samples to determine the
expression of CAT-1. As shown in Figure 1A–C, CAT-1 was
readily detected in mitochondria isolated from both sheep and
mice. The absence of contaminating sarcolemma was confirmed
by the absence of Na+K+ATPase in mice and by N-cadherin in
sheep. In mitochondrial samples isolated from failing hearts there
was a significant reduction in CAT-1 abundance compared with
controls in both sheep (73%, p,0.001) and mice (70%, p,0.01)
with heart failure (Figure 1A–E).
To corroborate the demonstration of CAT1 mitochondrial
protein, we next evaluated the uptake of [3H] L-arginine in both
models of HF. Preliminary L-arginine uptake time course studies
over 30 minutes in isolated cardiac mitochondria demonstrated a
progressive linear accumulation of [3H] L-arginine over time
ranges from 1–25 minutes (R2 = 0.9905 data not shown) and
accordingly an incubation time of 15 minutes was selected. In
parallel we investigated mitochondrial respiration using the
Seahorse platform. Mitochondrial viability was first confirmed
by the presence of respiratory control ratios of $4. State 3
respiration, as assessed in the presence of succinate, was however
significantly (p,0.05) decreased in mitochondria isolated from
failing hearts compared to controls (9976117 vs 17266198 pmol
O2/min). As shown in Figure 2, there was a concentration
dependent increase in L-arginine uptake in mitochondria isolated
from the normal heart. By contrast, L-arginine uptake was
significantly reduced in mitochondria from failing sheep and
mouse hearts when compared with healthy controls. L-arginine
transport by sheep mitochondria from control animals was
significantly reduced by the competitive inhibitor L-lysine (48%,
p,0.05), NEM (37%, p,0.05) and antimycin (32%, p,0.05) as
shown in Figure 3.
Nitric oxide production and nitrosative damage in HF
mitochondria
To evaluate whether altered CAT1 expression and L-arginine
transport was associated with an alteration in nitric oxide (NO)
production we evaluated mitochondrial NO release fluorometri-
cally. Under basal conditions, by DAF fluorescence, NO
generation was modestly but significantly reduced in failing sheep
mitochondria and compared to control (44046797 vs 40046852
rfu, p,0.05). In association, protein nitrosation, measured as 3-
nitrotyrosine, was significantly (p,0.05) higher in mitochondria
isolated from failing hearts (327670 nM) versus mitochondria
from healthy controls (109631 nM).
Effect of mitochondrial L-arginine availability during
cardiomyocyte stress
To extend the above observations we next aimed to investigate
the potential role of mitochondrial L-arginine transport in the
myocardial response to metabolic stress. To address this question
we generated an adeno-associated virus (AAV) encoding CAT1-
YFP-MTS that incorporates a mitochondrial targeting sequence
allowing for CAT-1 overexpression specifically in the mitochon-
dria and transfected isolated ventricular cardiomyocytes. Control
transfections were performed using AAV-YFP-MTS. Expression
and localisation of CAT-1 was confirmed using confocal
microscopy with MitoTracker Red as shown in Figure 4.
To confirm that mitochondria from cardiomyocytes transfected
with mitochondrial overexpression of CAT1 possessed an
increased capacity for arginine uptake and to generate NO from
arginine, we isolated mitochondria from CAT1-YFP-MTS and
YFP-MTS AAV transfected cardiomyocytes. Mitochondria isolat-
ed from CAT1-YFP-MTS transfected cardiomyocytes had signif-
icantly greater capacity for 3H arginine transport compared to
mitochondria from YFP-MTS transfected myocytes (16456211 vs
7726254 dpm/mg protein, p = 0.03, n= 5). In conjunction, we
determined the ability of 100 uM arginine to yield NO release as
assessed by DAF fluorescence. In CAT1 transfected mitochondria,
Figure 5. Bar graphs show oxygen consumption rates (OCR) due to basal respiration (top panel), OCR required for ATP turnover
(mid panel) and maximal respiratory capacity (lower panel) as evaluated by oxygen consumption rates in isolated cardiomyocytes
following hypoxia-reoxygenation. Cells were control untransfected (UT) or transfected with CAT1-YFP-MTS or YFP-MTS AAV6 for 72 hr then
subjected to 3 hr hypoxia-2 hr reoxygenation. Data is presented as mean 6 SEM. **p,0.01 and ***p,0.001 vs. non-transfected normoxic controls; d
p,0.05 and #p,0.01 vs. non-transfected hypoxia-reoxygenated NVCMs.
doi:10.1371/journal.pone.0104643.g005
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arginine caused a 1.7260.16 vs 1.2860.06 (p,0.05) fold rise in
NO production.
Basal respiration (Fig. 5A) was significantly decreased in
NVCMs following hypoxia-reoxygenation (447618 versus
657660 pmol O2/min in normoxic cells, p,0.01). By contrast,
NVCMs transfected with CAT1-YFP-MTS AAV were completely
protected and exhibit significantly improved basal OCR com-
pared with non-transfected cells following hypoxia-reoxygenation
(630618 pmol O2/min, p,0.05 versus non-transfected hypoxia-
reoxygenation). Hypoxia-reoxygenation significantly decreased
oxidative ATP turnover (p,0.001 versus normoxic controls,
Fig. 5B), which was also significantly restored in CAT1-YFP-MTS
AAV NVCMs (p,0.01 compared with non-transfected hypoxia-
reoxygenated NVCMs, Fig. 5B). There were no significant
changes in maximal respiratory capacity following hypoxia-
reoxygenation (Fig. 5C). There were no significant differences in
OCR or ATP turnover after hypoxia-reoxygenation in NVCMs
transfected with the control AAV (YFP-MTS AAV) compared
with non-transfected hypoxia-reoxygenated NVCMs (Fig. 5).
CAT1-YFP-MTS transfection had no effect on basal respiratory
rate (631653 pmol O2/min), ATP turnover (361637 pmol O2/
min) or maximal respiratory capacity (1680684 pmol O2/min) in
normoxic NVCM.
Exposure of NVCMs to hypoxia with reoxygenation signifi-
cantly reduced mitochondrial membrane potential (6061.4% of
normoxic controls, p,0.001) and significantly increased ROS
production (14462.3% of normoxic controls, p,0.001) as shown
in Table 1. NVCMs treated with antimycin A also exhibited
significantly decreased mitochondrial membrane potential
(6861.5% of untreated controls, p,0.001) and significantly
increased ROS generation (14264% of untreated controls, p,
0.001, Table 1). In conjunction, LDH release, a marker of cell
death or necrosis, significantly increased during both hypoxia-
reoxygenation and with antimycin A treatment (20068 and
255623 versus control, 760.2 arbitrary units x103, both p,0.001,
Table 1).
By contrast, NVCMs transfected with CAT1-YFP-MTS AAV
exhibit significantly reduced ROS generation and significantly
improved mitochondrial membrane potentials following both
hypoxia-reoxygenation or antimycin A treatment when compared
with their non-transfected controls (Table 1). ROS production
during hypoxia-reoxygenation was limited to 12161.6% in
CAT1-YFP-MTS AAV NVCMs versus 14462.3% in non-
transfected cells (p,0.01), whilst mitochondrial membrane poten-
tial depolarized to 7961% in CAT1-YFP-MTS AAV cells
compared with 6061.4% in non-transfected cells (p,0.001).
ROS production following antimycin A treatment was significant-
ly lower in CAT1-YFP-MTS AAV NVCMs than in non-
transfected cells (12061% versus 14264%, p,0.01) and mito-
chondrial membrane potential was significantly higher in CAT1-
YFP-MTS AAV cells (8661.1% compared with 6861.5% in non-
transfected controls, p,0.001). Furthermore, CAT1-YFP-MTS
NVCMs had significantly decreased LDH release following
hypoxia-reoxygenation and antimycin A treatment (p,0.001
and p,0.01 respectively compared with non-transfected control,
Table 1). There were no significant differences in ROS genera-
tion, mitochondrial membrane potential or LDH release after
2 hrs reoxygenation or with antimycin A treatment in NVCMs
transfected with the control AAV (YFP-MTS AAV) compared
with relevant non-transfected cells (Table 1). There was also no
significant difference in LDH release in normoxic cells transfected
with either CAT1-YFP-MTS or YFP-MTS AAV when compared
with non-transfected normoxic controls.T
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Discussion
In the present study we aimed to determine whether
mitochondria possess a specific transport system for the translo-
cation of L-arginine from the cytoplasm and to investigate its role
in the pathophysiology of cardiovascular disease states associated
with heightened oxidative stress, specifically heart failure and
hypoxia-reoxygenation stress. Our study was predicated upon
emerging evidence that NO plays an important role in the
regulation of several mitochondrial processes and that mitochon-
dria may contain enzymatic systems including NOS which
generate NO [10].
We demonstrated evidence for the concentration dependent
accumulation of L-arginine in the mitochondria of both mice and
sheep. The plasmalemmal transport of L-arginine in many cell
types including cardiomyocytes is predominantly mediated by the
biochemical system y+ carrier, which is principally represented by
the CAT-1 transporter [23]. The presence of such a transporter in
the mitochondria has previously remained unclear in mammalian
cells. Further evaluation by western blotting on isolated cardiac
mitochondria and confocal microscopy of isolated cardiomyocytes
confirmed the presence of CAT-1 in mitochondria, thus providing
new insights into the mechanism responsible for the transport of L-
arginine into mitochondria. Previously studies have reported the
presence of a mitochondrial ornithine transporter in yeast, which
exhibited some capacity for L-arginine transport with a relatively
low Km [24]. Additionally a mitochondrial arginase has also been
described [25], together suggesting the presence of a complex
system for the regulation of intra-mitochondrial L-arginine
content. In our study we showed that the mitochondrial transport
of L-arginine was significantly reduced by the cationic amino acid
L-lysine consistent with a y+ system mediated transport system.
The present study did not investigate the precise localization of the
mitochondrial CAT1 transporter. Furthermore we did not
establish the relationship between transporter kinetics and the
influence of various mitochondrial substrates.
Having established the presence of a mitochondrial CAT-1 L-
arginine, we aimed to determine whether mitochondrial CAT1
expression was altered in heart failure. We found that both
mitochondrial L-arginine uptake and mitochondrial expression of
the CAT-1 L-arginine transporter were significantly reduced in
the failing heart, in both models of heart failure. These data are
consistent with our previous findings that depressed vascular and
myocardial L-arginine transport plays a key role in the
pathophysiology of a range of cardiovascular disorders such as
hypertension and heart failure [15,26,27]. In the context of heart
failure, most previous studies of arginine transport have been
conducted in relation to the concomitant decrease in endothelial
function, by virtue of its influence on NO production[26].
Similarly, it has been proposed that diminished endothelial
arginine transport could contribute to the impairment of
endothelial function in hypertension [28,29]. Mechanistically,
previous studies of CAT1 activity and expression demonstrated
negative effects of angiotensin II and particularly protein kinase C,
of which both have pathophysiologic relevance to heart failure
[30]. In the context of the present study, a concomitant decrease in
plasmalemmal arginine transport would be expected to further
magnify the effects of a decrease in mitochondrial arginine
transport on mitochondrial function. In relation to the present
study, we did not specifically study the mechanism responsible for
the regulation of mitochondrial CAT1 expression.
In the current study we also found that mitochondria isolated
from failing hearts have significantly lower NO production and
significantly higher levels of 3-nitrotyrosine, indicative of increased
oxidative/nitrosative stress. 3-nitrotyrosine, a widely used marker
of oxidative and nitrosative damage in human and animal disease
states, is formed when peroxynitrite attacks tyrosine residues in
proteins. Peroxynitrite is known to cause irreversible inhibition of
many mitochondrial components including the respiratory chain
(specifically complex I and cytochrome c oxidase), the Kreb’s cycle
enzyme aconitase and Mn-superoxide dismutase [31].
To further investigate the notion that altered mitochondrial L-
arginine transport may influence the overall cellular response to
oxidative stress we examined whether augmented mitochondrial
L-arginine would provide cellular protection during hypoxia-
reoxygenation stress. Ventricular cardiomyocytes with mitochon-
drial overexpression of CAT1 showed a significant decrease in
ROS production, perseveration of mitochondrial membrane
potential together with evidence of significantly less cellular injury
following either hypoxia-reoxygenation or antimycin A exposure.
Furthermore, the deleterious effects of hypoxia-reoxygenation on
mitochondrial respiration and ATP turnover were attenuated by
enhanced mitochondrial CAT1 expression. Although we did not
examine the effects of increased mitochondrial CAT1 expression
in an experimental model of heart failure, we hypothesise that it
would be beneficial given that heart failure is associated with
elevated oxidative stress and that mitochondrial arginine transport
is reduced as demonstrated above.
Our findings of a cellular protective effect of increased
mitochondrial L-arginine transport and NO production are
entirely consistent with the findings of Chouchani and colleagues
who demonstrated that S-nitrosation of complex I, using a
mitochondrial selective NO donor, provided cardioprotection by
reducing oxidative damage [7]. Similarly, S-nitrosation of complex
I by nitrite has also been shown to be cardioprotective [32]. As
such, S-nitrosation of key cysteine residues could protective effects
during ischemic injury by preventing the irreversible effects of
exposure to peroxynitrite. For example, peroxynitrite can cause
direct permeabilisation of mitochondrial membranes leading to
the formation of mitochondrial permeability transition pore
(MPTP) with subsequent inhibition of ATP synthesis which can
lead to cellular necrosis [33]. High concentrations of NO may
transiently modify mitochondrial oxygen consumption by inter-
acting with cytochrome c oxidase [34]. Nitric oxide has also been
reported to exert other aspects of mitochondrial function including
the prevention of mitochondrial calcium accumulation, activating
expression of a number of mitochondrial proteins including PGC-
1a, increasing the production of mitochondrial DNA or inhibiting
the pathway of apoptosis [34–37]. Other studies suggest that
reduced mitochondrial NO availability impairs mitochondrial
biogenesis and decreased myocardial NO levels induce a switch
from fatty acid metabolism to glycolytic metabolism [38].
In the present study we did not aim to specifically determine the
source of mitochondrial NO. The presence of a constitutively
expressed mitochondrial NOS enzyme has been proposed based
on the demonstration of mitochondrial NO generation using a
range of techniques including electroparamagnetic spin trapping,
radiometry, chemiluminescence and fluorescence microscopy [10],
however this remains controversial. A mitochondrial NOS has
been proposed to be a component of the inner membrane and
which generates NO in a calcium-dependent manner [39–46].
The identity of a putative mitochondrial NOS also remains
speculative, with some evidence for a neuronal isoform NOS
based upon proteomic analysis of mitochondrial extracts and the
absence of mitochondrial NO production in nNOS knockout mice
[47,48]. The mechanism by which a putative mtNOS localises to
the mitochondria is unknown, but may include post-translational
modifications or interactions with other proteins [35]. Whilst our
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observations are consistent with a paradigm in which the
mitochondrial L-arginine transporter plays a key role in providing
substrate to a mitochondrial NOS which in turn generates NO to
regulate mitochondrial function and to provide protection during
cellular stress, it is possible that the mitochondrial L-arginine
transporter influences mitochondrial function in other ways. For
example the generation of ornithine via arginase could participate
in other mitochondrial bioenergetic activities.
Conclusion
Our study provides the first evidence for the presence of a CAT-
1 isoform L-arginine transporter in mammalian cardiac mito-
chondria. We demonstrated a significant reduction in L-arginine
uptake and NO production in mitochondria obtained from the
failing heart and this was accompanied by evidence of nitrosative
modification of the mitochondrial membrane. Increasing mito-
chondrial L-arginine availability by transfection of a mitochon-
drially targeted CAT-1 significantly improved cardiomyocyte
responses to mitochondrial stresses, reducing oxidative stress and
improving survival. Taken together, these data provide new
insights into the nature of myocardial mitochondrial L-arginine
transport, its role in mitochondrial biology and the pathogenesis of
cardiovascular disease.
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